CSPC Pharmaceutical Group Limited — Capital/Financing Update 2018

Dec 11, 2018

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States, the People’s Republic of China or elsewhere.

==> picture [62 x 90] intentionally omitted <==

CSPC PharmaCeutiCal GrouP limited 石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

ProGreSS uPdate oN the ProPoSed SPiN-oFF aNd SeParate liStiNG oF CSPC XNW GrouP oN the SheNZheN StoCK eXChaNGe

Reference is made to the announcement of the Company dated 27 December 2017 (the “ announcement ”) in relation to the Proposed A Share Listing of CSPC XNW on SZSE. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

On 11 December 2018, the Public Offering Review Committee (the “ PorC ”) of the CSRC reviewed the application of CSPC XNW for the Proposed A Share Listing on the ChiNext of the SZSE. According to the review results announcement of the 188th meeting of 2018 published on the website of CSRC (the “ results announcement ”), the proposed initial public offering of new shares of CSPC XNW on the ChiNext of the SZSE was reviewed and passed by the PORC.

Notwithstanding the results announcement, shareholders and potential investors of the Company should note that there is no assurance that the Proposed a Share listing will take place or as to when it will take place. the Proposed a Share listing will remain subject to, among other things, obtaining the formal written approval for the initial public offering from the CSrC and the SZSe having reviewed and consented to the initial public offering and listing of such shares on the ChiNext.

— 1 —

Further announcement(s) will be made by the Company in relation to the Proposed A Share Listing as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. if in any doubt, shareholders and potential investors of the Company are recommended to consult their professional advisers.

By order of the Board CSPC Pharmaceutical Group limited Cai dongchen

Chairman

Hong Kong, 11 December 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. LU Hua, Dr. LI Chunlei, Mr. ZHANG Cuilong, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as nonexecutive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Professor LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

— 2 —